乳癌核心针活检市场 - 全球产业规模、份额、趋势、机会和预测，按技术、最终用途和地区、竞争细分，2019-2029F

2023 年，全球乳癌核心针切片市场估值为8 亿美元，预计在预测期内将出现令人印象深刻的成长，到2029 年复合年增长率为8.90%。用于提取组织的医疗程序从乳房样本进行彻底的分析和诊断。它是一种微创技术，用于确定乳房异常的恶性或良性，特别是在乳房 X 光检查、超音波或 MRI 扫描发现可疑结果后。与手术活检相比，空心针活检涉及更小的切口或穿刺，从而减少组织创伤并加快恢復时间。这些活检提供了对于准确的病理检查至关重要的组织样本，有助于精确表征乳房异常。鑑于乳癌作为健康问题的全球重要性，对诸如空心针活检等精确有效的诊断程序的需求不断增长。对早期发现的重视强调了定期筛检和及时诊断的重要性，进一步凸显了空心针活检在促进及时、准确诊断方面的作用。成像技术的进步提高了对可疑病变的检测，推动了对空心针活检以确认其性质的需求。

市场概况
预测期	2025-2029
2023 年市场规模	8亿美元
2029 年市场规模	13.4亿美元
2024-2029 年复合年增长率	8.90%
成长最快的细分市场	基于 MRI 的乳房活检
最大的市场	北美洲

此外，随着肿瘤学向个人化医疗和标靶治疗的转变，芯针活检促进的精确肿瘤表征变得越来越重要。公众宣传活动和有组织的乳癌筛检计画等措施鼓励女性接受常规筛检，从而提高检出率并增加对活检程序的需求。

主要市场驱动因素

技术创新

老年人口不断增加

筛检和宣传活动

主要市场挑战

费用和报销问题

诊断准确性和误报/阴性

主要市场趋势

偏好微创手术

细分市场洞察

技术洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球乳癌核心针切片市场的影响

第 5 章：客户之声

第 6 章：全球乳癌核心针切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按技术分类（基于 MRI 的乳房切片检查、基于超音波的乳房切片检查、基于乳房 X 光摄影（立体定位）的乳房切片检查、基于 CT 的乳房切片检查、其他基于影像的乳房切片检查）
  • 按最终用途（医院和诊断实验室、製药和生物技术公司、学术和研究机构）
  • 按地区
  • 按公司划分 (2023)
• 市场地图

第 7 章：亚太地区乳癌核心针切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按最终用途
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 8 章：欧洲乳癌核心针切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按最终用途
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 9 章：北美乳癌核心针切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按最终用途
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 10 章：南美洲乳癌核心针切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按最终用途
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲乳癌核心针活检市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按最终用途
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 司机
• 挑战

第 13 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 14 章：全球乳癌核心针切片市场：SWOT 分析

第 15 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第 16 章：大环境分析

第17章：竞争格局

• Intact Medical Corporation
• Ethicon Endo Surgery
• Galini SRL
• Leica Biosystems Nussloch GmbH
• Hologic Inc.
• Argon Medical Devices
• Encapsule Medical Devices LLC.
• Cook Medical Incorporated
• Becton & Dickinson Company
• CR Bard, Inc

第 18 章：策略建议

第19章调查会社について・免责事项

Global Breast Cancer Core Needle Biopsy Market was valued at USD 0.80 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.90% through 2029. A Breast Cancer Core Needle Biopsy is a medical procedure utilized for extracting tissue samples from the breast to conduct thorough analysis and diagnosis. It serves as a minimally invasive technique for determining the malignancy or benignity of breast anomalies, particularly following suspicious findings on mammograms, ultrasounds, or MRI scans. Compared to surgical biopsies, core needle biopsies involve smaller incisions or punctures, resulting in reduced tissue trauma and quicker recovery times. These biopsies provide tissue samples crucial for accurate pathological examination, aiding in the precise characterization of breast abnormalities. Given the global significance of breast cancer as a health concern, there is a growing demand for precise and efficient diagnostic procedures like core needle biopsies. The emphasis on early detection underscores the importance of regular screenings and prompt diagnosis, further highlighting the role of core needle biopsies in facilitating timely and accurate diagnosis. Advancements in imaging technologies have improved the detection of suspicious lesions, driving the need for core needle biopsies to confirm their nature.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 0.80 Billion
Market Size 2029	USD 1.34 Billion
CAGR 2024-2029	8.90%
Fastest Growing Segment	MRI-Based Breast Biopsy
Largest Market	North America

Also, with the shift towards personalized medicine and targeted therapies in oncology, precise tumor characterization facilitated by core needle biopsies is increasingly crucial. Initiatives such as public awareness campaigns and organized breast cancer screening programs encourage women to undergo routine screenings, resulting in higher detection rates and an increased demand for biopsy procedures.

Key Market Drivers

Technological Innovations

Advancements in imaging technologies such as ultrasound, mammography, and MRI have significantly improved the accuracy of image-guided core needle biopsies. Real-time imaging enables precise guidance of the biopsy needle to the target area, enhancing tissue sampling accuracy. Digital breast tomosynthesis, or 3D mammography, offers clearer and more detailed breast tissue images, aiding in biopsy accuracy through multiple views from different angles. Robotic-assisted biopsy systems provide heightened precision and control, minimizing variability from human factors and improving sampling accuracy. Vacuum-assisted biopsy (VAB) systems use vacuum pressure to gently draw tissue into the biopsy needle, enhancing efficiency and diagnostic yield. Non-invasive localization systems, enabled by wireless technology, assist surgeons in precisely locating and removing marked breast lesions post-biopsy. Integrated software tools with imaging systems aid in planning biopsy paths, calculating needle trajectory, and optimizing sample collection, resulting in more accurate and efficient biopsies. Dual-Energy Contrast-Enhanced Digital Mammography combines contrast-enhanced mammography with 3D imaging, facilitating better visualization of cancer-associated abnormal blood vessels and guiding more accurate biopsies.

Specialized biopsy devices designed for MRI-guided biopsies are crafted from non-magnetic materials, ensuring compatibility with MRI scanners. Liquid biopsies, though not traditional core needle biopsies, involve analyzing blood samples for circulating tumor DNA (ctDNA) or biomarkers, offering genetic tumor insights without tissue sampling. Artificial Intelligence (AI) and Machine Learning enhance medical image analysis, aiding in identifying subtle abnormalities and assisting in biopsy path planning and lesion nature prediction. Needle design innovations prioritize reduced tissue damage, improved accuracy, and patient comfort. Features like self-contained spring-loaded needles and beveled-tip designs, equipped with sensors for real-time feedback on tissue stiffness and proximity to critical structures, elevate sampling precision. These advancements collectively contribute to the growth of the Global Breast Cancer Core Needle Biopsy Market.

Growing Geriatric Population

As the population ages, the occurrence of various health conditions, including breast cancer, tends to rise. Breast cancer risk escalates with age, particularly among the elderly population, necessitating more frequent screenings and diagnostic procedures like core needle biopsies. Older individuals face a heightened risk of delayed diagnosis, often stemming from factors such as reduced participation in screening programs. Such delays may lead to the requirement for more invasive diagnostic measures like core needle biopsies. Elderly patients commonly present with comorbidities and complex medical backgrounds, complicating treatment decisions. Core needle biopsies offer crucial insights into tumor characteristics, facilitating appropriate treatment planning. Tailored treatment plans, considering factors like overall health, medical history, and cancer aggressiveness, are often necessary for older patients, and core needle biopsies play a pivotal role in providing the requisite information.

Core needle biopsies are generally less invasive with shorter recovery periods compared to surgical biopsies, a significant advantage for older patients with potentially diminished physical resilience. Breast cancer screening guidelines advocate regular mammograms for specific age groups of women. As women age, the likelihood of requiring further evaluation via core needle biopsies due to suspicious mammogram findings rises. With advancements in healthcare and quality of life, many seniors are living longer, making timely detection and diagnosis of breast cancer increasingly critical for maintaining quality of life. Early detection significantly enhances treatment outcomes, especially considering the heightened risk of aggressive tumors among the geriatric population. As the demand for geriatric healthcare services surges, facilities specializing in elderly care are more inclined to provide comprehensive diagnostic services, including core needle biopsies. Public health campaigns targeting breast cancer awareness among the elderly encourage participation in screenings and diagnostic procedures, further fueling demand for the Global Breast Cancer Core Needle Biopsy Market.

Screening and Awareness Campaigns

These campaigns are designed to educate the public about breast cancer detection, promote regular screenings, and advocate for early diagnosis. By highlighting the importance of early detection in improving breast cancer outcomes, they stimulate demand for diagnostic procedures like core needle biopsies. Encouraging individuals, especially those at higher risk or in specific age groups, to undergo breast cancer screenings leads to increased detection of suspicious lesions requiring further evaluation through core needle biopsies. Routine screenings, such as mammograms, often reveal abnormalities requiring additional testing, potentially resulting in core needle biopsy recommendations to determine the nature of the abnormality.

Awareness campaigns play a vital role in educating individuals about the diagnostic process, including core needle biopsies, to alleviate concerns and promote acceptance of the procedure. Targeting specific demographics, such as particular age groups or high-risk populations, ensures that those who would benefit most from core needle biopsies understand their importance. Promoting routine health check-ups, during which healthcare providers may recommend screenings and subsequent diagnostic procedures like core needle biopsies, is a key aspect of these campaigns.

Empowering individuals with knowledge about their healthcare options encourages proactive behavior, such as requesting necessary diagnostic procedures. Successful awareness campaigns lead to more early-stage breast cancer diagnoses, potentially reducing breast cancer mortality rates. Community events, workshops, and support groups organized as part of these campaigns create a sense of community and encourage individuals to prioritize their health, including undergoing necessary diagnostic procedures. This dynamic contributes to the increasing demand in the Global Breast Cancer Core Needle Biopsy Market.

Key Market Challenges

Cost and Reimbursement Issues

These challenges can impact both healthcare providers and patients, affecting the adoption and accessibility of core needle biopsy procedures. Healthcare facilities need to invest in specialized equipment, imaging technologies, and trained personnel to offer core needle biopsies. The initial investment required for these resources can be substantial. Core needle biopsies involve various costs, including equipment maintenance, consumables, imaging guidance, and pathology analysis. These costs can contribute to the overall expenses of the procedure. Healthcare providers often rely on reimbursements from insurance companies or government programs to cover the costs of medical procedures. Inadequate reimbursement rates for core needle biopsies might discourage providers from offering these services. Reimbursement policies can vary based on factors such as the specific procedure, facility type, geographical region, and insurance coverage. This variability can lead to uncertainty for both providers and patients. In some cases, insurance plans might not cover the full cost of core needle biopsies or might not cover them at all. This financial burden can discourage patients from undergoing the procedure. Healthcare providers often need to go through pre-authorization processes, submitting detailed documentation to insurance companies to demonstrate the medical necessity of the procedure. This administrative burden can delay patient care. Patients may be required to cover a portion of the procedure's cost through co-pays, deductibles, or other out-of-pocket expenses. High out-of-pocket costs might deter patients from choosing core needle biopsies.

Diagnostic Accuracy and False Positives/Negatives

Accurate diagnostic results from core needle biopsies are essential for determining the nature of breast lesions. Oncologists rely on these results to formulate effective treatment plans tailored to each patient's condition. False positives (incorrectly identifying cancer) and false negatives (missing cancer) can lead to inappropriate or delayed treatment decisions. Accurate biopsy results are essential for choosing the most suitable treatment strategy. False-positive results can lead to unnecessary anxiety and stress for patients, while false negatives might lead to delayed diagnosis and treatment, negatively affecting patient outcomes and mental well-being. In cases of inconclusive or inaccurate core needle biopsy results, patients might need to undergo rebiopsy or additional diagnostic procedures, increasing healthcare costs and patient discomfort. Incorrect diagnoses can strain healthcare resources by requiring additional medical interventions and treatments that could have been avoided with accurate initial diagnoses. Healthcare providers need to implement quality control and assurance measures to minimize the risk of false results. Ensuring consistent accuracy across different facilities and professionals can be challenging. Accurate interpretation of core needle biopsy samples requires skilled pathologists who can differentiate between various breast tissue abnormalities. Ensuring enough skilled pathologists is essential.

Key Market Trends

Preference for Minimally Invasive Procedures

Minimally invasive procedures involve smaller incisions or needle insertions, leading to less tissue trauma and reduced post-procedure discomfort and pain. Patients are more likely to choose core needle biopsies over surgical options due to the associated comfort. Minimally invasive procedures typically result in quicker recovery times compared to traditional surgeries. This is especially beneficial for patients who wish to return to their daily activities as soon as possible. Many minimally invasive core needle biopsies can be performed on an outpatient basis. This convenience allows patients to undergo the procedure and return home on the same day, reducing the need for hospitalization. Minimally invasive techniques usually carry a lower risk of infection, bleeding, and other complications commonly associated with more invasive surgical procedures. Minimally invasive procedures often leave smaller scars or no visible scars, which can be important for patients concerned about cosmetic outcomes. Core needle biopsies are often performed under local anesthesia, reducing the risks associated with general anesthesia and allowing patients to remain awake and comfortable during the procedure. The preference for minimally invasive procedures aligns with patients' desire for less invasive approaches to healthcare. Patients are more likely to agree to recommended procedures when they are perceived as less invasive. Minimally invasive core needle biopsies can be performed in a variety of medical settings, including clinics and outpatient centers, making them more accessible to a broader patient population.

Segmental Insights

Technology Insights

In 2023, the Global Breast Cancer Core Needle Biopsy Market dominated by MRI-Based Breast Biopsy segment in the forecast period and is predicted to continue expanding over the coming years. MRI (Magnetic Resonance Imaging) offers high-resolution images of breast tissue, making it highly accurate in identifying suspicious lesions or abnormalities. This accuracy is crucial for guiding the biopsy needle to the precise location of the abnormality, which enhances the diagnostic yield of the biopsy. MRI is particularly effective in detecting and characterizing complex breast lesions that might be difficult to visualize using other imaging modalities. This makes it a valuable tool for identifying lesions that require further investigation through biopsy. For individuals with a high risk of breast cancer due to family history or genetic mutations (e.g., BRCA1/BRCA2), MRI-based screening and biopsies can offer better sensitivity in detecting early-stage cancers or precancerous lesions.

Regional Insights

The North America region dominates the Global Breast Cancer Core Needle Biopsy Market in 2023. North America, particularly the United States and Canada, has a well-developed and advanced healthcare infrastructure. This includes state-of-the-art medical facilities, research institutions, and a robust regulatory environment that fosters innovation and rapid adoption of new medical technologies. The region has a history of early adoption of advanced medical technologies. This includes diagnostic tools and procedures like breast cancer core needle biopsies. Healthcare providers in North America are often quick to embrace new techniques that can enhance patient care and outcomes. Many leading medical device manufacturers and biotechnology companies are based in North America. This concentration of research and development efforts contributes to the creation of innovative biopsy devices and techniques that attract global attention. North America places a significant emphasis on cancer screening, early detection, and diagnosis. This focus drives the demand for accurate and minimally invasive diagnostic procedures like core needle biopsies.

Key Market Players

Intact Medical Corporation

Ethicon Endo Surgery

Galini SRL

Leica Biosystems Nussloch GmbH

Hologic Inc.

Argon Medical Devices

Encapsule Medical Devices LLC.

Cook Medical Incorporated

Becton & Dickinson Company

C.R. Bard, Inc.

Report Scope:

In this report, the Global Breast Cancer Core Needle Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Core Needle Biopsy Market, By Technology:

MRI-Based Breast Biopsy Ultrasound-Based Breast Biopsy Mammography-Based (Stereotactic) Breast Biopsy CT-Based Breast Biopsy Other Image Based Breast Biopsy

Breast Cancer Core Needle Biopsy Market, By End-user:

Hospitals & Diagnostic Laboratories Pharmaceutical & Biotechnology companies Academic & Research Institutes

Breast Cancer Core Needle Biopsy Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Core Needle Biopsy Market.

Available Customizations:

Global Breast Cancer Core Needle Biopsy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Breast Cancer Core Needle Biopsy Market

5. Voice of Customer

6. Global Breast Cancer Core Needle Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology (MRI-Based Breast Biopsy, Ultrasound-Based Breast Biopsy, Mammography-Based (Stereotactic) Breast Biopsy, CT-Based Breast Biopsy, Other Image Based Breast Biopsy)
  • 6.2.2. By End Use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology companies, Academic & Research Institutes)
  • 6.2.3. By Region
  • 6.2.4. By Company (2023)
• 6.3. Market Map

7. Asia Pacific Breast Cancer Core Needle Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By End Use
  • 7.3.2. India Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By End Use
  • 7.3.3. Australia Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By End Use
  • 7.3.4. Japan Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By End Use
  • 7.3.5. South Korea Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By End Use

8. Europe Breast Cancer Core Needle Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By End Use
  • 8.3.2. Germany Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By End Use
  • 8.3.3. Spain Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By End Use
  • 8.3.4. Italy Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By End Use
  • 8.3.5. United Kingdom Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By End Use

9. North America Breast Cancer Core Needle Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By End Use
  • 9.3.2. Mexico Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By End Use
  • 9.3.3. Canada Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By End Use

10. South America Breast Cancer Core Needle Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By End Use
  • 10.3.2. Argentina Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By End Use
  • 10.3.3. Colombia Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By End Use

11. Middle East and Africa Breast Cancer Core Needle Biopsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Technology
  • 11.2.2. By End Use
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Technology
      • 11.3.1.2.2. By End Use
  • 11.3.2. Saudi Arabia Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Technology
      • 11.3.2.2.2. By End Use
  • 11.3.3. UAE Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Technology
      • 11.3.3.2.2. By End Use

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Breast Cancer Core Needle Biopsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. Intact Medical Corporation
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Financials (If Listed)
  • 17.1.4. Product & Service Offerings
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel
  • 17.1.7. SWOT Analysis
• 17.2. Ethicon Endo Surgery
• 17.3. Galini SRL
• 17.4. Leica Biosystems Nussloch GmbH
• 17.5. Hologic Inc.
• 17.6. Argon Medical Devices
• 17.7. Encapsule Medical Devices LLC.
• 17.8. Cook Medical Incorporated
• 17.9. Becton & Dickinson Company
• 17.10.C.R. Bard, Inc

18. Strategic Recommendations

19. About Us & Disclaimer